Depending upon your perspective, “emerging” biotech could mean any number of things, ranging all the way from the recent spinout of an academic lab to a publicly held company developing a therapeutic that has not yet reached the marketplace. My company, Respana Therapeutics (a finalist in North America Advance Biotech Grant Program) sits at the […]

Tech transfer appears on the agenda of almost every biotech company. After identifying a suitable molecule, biotechs need support from external partners on the way to commercialization. However, many fear that tech transfer could slow them down or that they may be locked in with royalty fees. Working with the right partner can make all […]

Navigating through the evolving regulatory landscape can be a challenge, especially for early-stage biotechnology companies developing a drug for the first time. The production process developed for new drug candidates is governed by a stringent and extensive set of requirements to which every manufacturer must adhere. Understanding and properly applying these regulations are critical to […]

The Chemical Engineering magazine has published an overview of the biopharmaceutical industry written by Merck/MilliporeSigma employees. This article highlights the role of chemical engineers, and sets the stage for subsequent articles that will explore additional aspects of the industry leading the charge in the battle against the pandemic. The series will provide a behind-the-scenes look […]